Theraclone Sciences
Latest round
- Series C
Last raised
- May 2015
Total raised
- $56M
Investors
- 10
About Theraclone Sciences
Founded in 2004, Theraclone Sciences operates out of Seattle, US, specializing in human monoclonal antibody development. Theraclone's founder, who has not been publicly named, has a history of involvement in biotechnology ventures. The company's operations and strategies have remained consistent since its inception, focusing on antibody discovery and licensing.Theraclone Sciences specializes in the discovery and development of human monoclonal antibodies through its advanced screening platform technology. The company's primary focus is on identifying rare antibodies that can effectively target infections and diseases, providing innovative therapeutic options. Among its notable offerings, Theraclone has licensed its HIV broadly neutralizing fully-human antibodies to Gilead, which are being developed as part of an HIV-cure regimen. Additionally, the company has partnered with OncoResponse, allowing the application of its platform technology within the oncology sector.Theraclone Sciences generates revenue through strategic licensing agreements and partnerships with pharmaceutical companies, allowing for the commercialization of its proprietary antibody products. The firm engages in business transactions primarily through B2B relationships, where it licenses its technology and antibody candidates to larger firms in exchange for royalties and milestone payments based on developmental progress. The revenue structure is bolstered by these partnerships, with potential for ongoing revenue streams from successful product developments. The company plans to design and launch new monoclonal antibody products aimed at addressing unmet medical needs in infectious diseases and oncology. Additionally, Theraclone is exploring expansion into international markets beyond North America and Europe, with specific strategies to penetrate emerging markets in Asia by 2025.
Who invested in Theraclone Sciences
10 investors across 7 rounds
See all investors in Theraclone Sciences
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series C
May 6, 2015
Amount
$3.1M
Investors
Series B
Mar 25, 2013
Amount
$8M
Investors
Series B
Sep 9, 2011
Amount
$11M
Investors
Series B
Mar 17, 2010
Amount
$1.5M
Investors
Series B
Mar 19, 2007
Amount
$29M
Investors
Series A
Feb 6, 2006
Amount
$1.5M
Investors
Series A
Oct 1, 2004
Amount
$2M
Investors
Questions about Theraclone Sciences
Who invested in Theraclone Sciences?
Theraclone Sciences has 10 investors on record across 7 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Theraclone Sciences raised?
Theraclone Sciences has raised 7 venture rounds. Sign up free to see how much each round raised and the total.
When did Theraclone Sciences last raise money?
Theraclone Sciences's most recent round on record is a Series C, in May 2015.
What does Theraclone Sciences do?
Founded in 2004, Theraclone Sciences operates out of Seattle, US, specializing in human monoclonal antibody development.
Where is Theraclone Sciences headquartered?
Theraclone Sciences is headquartered in Seattle, US.
Which VCs invest in companies like Theraclone Sciences?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Theraclone Sciences's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series C
Raising like Theraclone Sciences? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.